Publications

A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ, Weidhaas JB.
Cancer Res. 2008 Oct 15;68(20):8535-40.PMID: 18922928 [PubMed - indexed for MEDLINE] Free text

A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.
Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, McClean MD, Marsit CJ, Kelsey KT.
Carcinogenesis. 2009 Jun;30(6):1003-7. Epub 2009 Apr 20.PMID: 19380522 [PubMed - indexed for MEDLINE] Free text Related citations

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB.
Cancer Res. 2010 Aug 15;70(16):6509-15. Epub 2010 Jul 20.PMID: 20647319 [PubMed - indexed for MEDLINE]

Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.
Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, van den Ouweland AM, Weidhaas JB.
Breast Cancer Res Treat. 2010 Jul 30. [Epub ahead of print] PMID: 20676756 [PubMed - as supplied by publisher] Related citations

The BRCA1 30-UTR: 5711þ421T=T_5711þ1286T=T Genotype Is a Possible Breast and Ovarian Cancer Risk Factor
Malinee Pongsavee,1 Vichanan Yamkamon,1 Sumana Dakeng,1 Pornchai O-charoenrat,2
Duncan R. Smith,3 Grady F. Saunders,4, and Pimpicha Patmasiriwat1
GENETIC TESTING AND MOLECULAR BIOMARKERS
Volume 13, Number 3, 2009 Mary Ann Liebert, Inc. Pp. 307-317

Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk
Cory Pelletier,1,2 William C. Speed,2 Trupti Paranjape,1 Katie Keane,3 Rachel Blitzblau,1 Antoinette Hollestelle,4 Kyan Safavi,1 Ans van den Ouweland,5 Daniel Zelterman,6 Frank J. Slack,7 Kenneth K. Kidd2 and Joanne B. Weidhaas1,*
Cell Cycle 10:1, 90-99; January 1, 2011

Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients.
Ruzzo A, Canestrari E, Galluccio N, Santini D, Vincenzi B, Tonini G, Magnani M, Graziano F.
Ann Oncol. 2010 Oct 6. [Epub ahead of print] No abstract available. PMID: 20926546 [PubMed - as supplied by publisher] Related citations

Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, Rocchi M, Vincenzi B, Salvatore L, Cremolini C, Spoto C, Catalano V, D'Emidio S, Giordani P, Tonini G, Falcone A, Magnani M.
Pharmacogenomics J. 2010 Oct;10(5):458-64. Epub 2010 Feb 23.PMID: 20177422 [PubMed - in process] Related citations

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.
Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, Labonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ.
Ann Oncol. 2010 Jul 5. [Epub ahead of print] PMID: 20603437 [PubMed - as supplied by publisher] Related citations

Kras Mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer.
Nelson HH, Christensen BC, Plaza SL, Wiencke JK, Marsit CJ, Kelsey KT.
Lung Cancer. 2010 Jul;69(1):51-3.Epub 2009 Oct 24. PMID: 19854534